Table 5.
Characteristics of patients in the CRIDECO study.
| Characteristics of Study Participants (n = 512) |
Cognitive Decline (n = 164) |
No Cognitive Decline (n = 348) |
|---|---|---|
| Age, years (mean (SD)) | 74.67 (7.91) | 68.09 (9.08) |
| Female (n (%)) | 123 (75%) | 255 (73.27%) |
| BMI (mean (SD)) | 27.15 (3.85) | 27.15 (3.90) |
| Drugs (mean (SD)) | 6.52 (3.31) | 5.74 (3.28) |
| Mean TAB ACB score (mean (SD)) | 1.08 (1.53) | 0.87 (1.37) |
| Mean TAB CALS score (mean (SD)) | 2.14 (1.88) | 1.62 (1.67) |
| TAB CALS score ≥ 3 (n (%)) | 61 (37.20%) | 86 (24.71%) |
| TAB ACB score ≥ 3 (n (%)) | 35 (21.34%) | 49 (14.10%) |
| MIS test (mean (SD)) | 4.44 (2.31) | 7.09 (0.99) |
| SPMSQ test (mean (SD)) | 2.99 (1.96) | 0.73 (0.78) |
| SVF test (mean (SD)) | 10.05 (3.82) | 16.10 (4.38) |
| Diabetes (n (%)) | 40 (24.39%) | 77 (22.13%) |
| Hypertension (n (%)) | 100 (60.98%) | 189 (54.31%) |
| Hypercholesterolemia (n (%)) | 82 (50%) | 159 (45.69%) |
| Depression (n (%)) | 62 (37.80%) | 100 (28.74%) |
SD = Standard Deviation; BMI = Body Mass Index; TAB ACB = Total Anticholinergic Burden measured by Anticholinergic Cognitive Burden Scale; TAB CALS = Total Anticholinergic Burden measured by CRIDECO Anticholinergic Load Scale; MIS = Memory Impairment Screen; SPMSQ = Short Portable Mental Questionnaire; SVF = Semantic Verbal Fluency Test.